ABCB1 and chronic myelogenous leukemia, BCR-ABL1 positive: ABCB1 overexpression is a pivotal mechanism of resistance to tyrosine kinase inhibitors (TKIs) in Chronic Myeloid Leukemia (CML), impacting drugs such as imatinib, nilotinib, and dasatinib.